Nestlé Skin Health

nestleskinhealth.com

Nestlé Skin Health’s mission is to enhance people's quality of life and contribute to a healthier future through science-based solutions for skin health, leading to our vision - to change the way the world thinks about skin health. As one of the category’s leading companies, Nestlé Skin Health conducts ground-breaking product research to provide both the healthcare community and the consumer with an ongoing progression of innovative technologies and products to protect, serve and enhance skin health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ICECURE SUBMITS REGULATORY FILING IN VIETNAM FOR APPROVAL OF PROSENSE®

IceCure Medical Ltd | August 30, 2022

news image

IceCure Medical Ltd. developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction of Vietnam's Ministry of Health for the ProSense System and accessories. The application covers indications including benign and malignant breast tumors, benign and malignant lung tumors, benign ...

Read More

POSITIVE CHMP APPROVAL FOR TAKEDA'S ALUNBRIG IN ALK ADVANCED NON-SMALL LUNG CANCER

Pharmafile: Home | March 04, 2020

news image

The decision was based on Phase 3 comparing Alunbrig to crizotinib in the same indication. The findings for Alunbrig showed a 69% reduction in risk of intracranial disease progression or death in patients with brain metastases according to a blinded independent review committee, and a 76% reduction according to investigators. The drug also demonstrated a median progression-free survival of 24 months, more than double the 11 months presented by crizotinib. Because of the complex nature of ALK+ NS...

Read More

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

news image

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More
news image

BUSINESS INSIGHTS

ICECURE SUBMITS REGULATORY FILING IN VIETNAM FOR APPROVAL OF PROSENSE®

IceCure Medical Ltd | August 30, 2022

IceCure Medical Ltd. developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction of Vietnam's Ministry of Health for the ProSense System and accessories. The application covers indications including benign and malignant breast tumors, benign and malignant lung tumors, benign ...

Read More
news image

POSITIVE CHMP APPROVAL FOR TAKEDA'S ALUNBRIG IN ALK ADVANCED NON-SMALL LUNG CANCER

Pharmafile: Home | March 04, 2020

The decision was based on Phase 3 comparing Alunbrig to crizotinib in the same indication. The findings for Alunbrig showed a 69% reduction in risk of intracranial disease progression or death in patients with brain metastases according to a blinded independent review committee, and a 76% reduction according to investigators. The drug also demonstrated a median progression-free survival of 24 months, more than double the 11 months presented by crizotinib. Because of the complex nature of ALK+ NS...

Read More
news image

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More
news image

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More